LivaNova PLC announced the strategic wind down of its Advanced Circulatory Support (ACS) Business Unit to focus on its core Cardiopulmonary and Neuromodulation units, with a complete transition expected by end of 2024. The company will integrate select ACS cannulae products into its Cardiopulmonary unit, while anticipating a positive impact on its 2024 operating income, despite expected restructuring charges.